Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 11/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 3/20 | 0.39 |
| ▸ | TPH1 | P17752 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24352213 | 0.84 | ALDH1A1 (0.43) | PDE9AF2CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL24352675 | 0.83 | F2 (0.42) | PDE9AF2CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL13078833 | 0.83 | ALDH1A1 (0.45) | PDE9AF2CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL24352537 | 0.81 | F2 (0.39) | PDE9AF2CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL14452034 | 0.79 | F2 (0.50) | F2 | |
| SCHEMBL18585073 | 0.78 | TPH1 (0.40) | PDE9AF2ALDH1A1POLBF10 | |
| SCHEMBL4611825 | 0.78 | LMNA (0.43) | PDE9AF2CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL30332313 | 0.78 | LMNA (0.43) | PDE9AF2CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL30640530 | 0.78 | TPH1 (0.40) | PDE9AF2ALDH1A1POLBF10 | |
| SCHEMBL24352536 | 0.78 | OPRM1 (0.38) | PDE9AF2CYP3A4CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | PDE9A 3252/4885F2 2851/4885CYP3A4 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.